[HTML][HTML] Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N Basset-Séguin, A Hauschild, R Kunstfeld… - European journal of …, 2017 - Elsevier
Abstract Background The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials. gov,
NCT01367665), assessed safety and efficacy of vismodegib—a first-in-class Hedgehog …
NCT01367665), assessed safety and efficacy of vismodegib—a first-in-class Hedgehog …
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N Basset-Séguin, A Hauschild, R Kunstfeld… - EUROPEAN JOURNAL …, 2017 - cris.unibo.it
Background The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials. gov,
NCT01367665), assessed safety and efficacy of vismodegib—a first-in-class Hedgehog …
NCT01367665), assessed safety and efficacy of vismodegib—a first-in-class Hedgehog …
[引用][C] Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N Basset-Séguin, A Hauschild, R Kunstfeld… - European Journal of …, 2017 - zora.uzh.ch
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N Basset-Séguin, A Hauschild, R Kunstfeld… - European Journal of …, 2017 - hal.science
BACKGROUND: The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials. gov,
NCT01367665), assessed safety and efficacy of vismodegib-a first-in-class Hedgehog …
NCT01367665), assessed safety and efficacy of vismodegib-a first-in-class Hedgehog …
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
N Basset-Séguin, A Hauschild, R Kunstfeld… - European journal of …, 2017 - sonar.ch
RESULTS Evaluable adult patients (N= 1215, 1119 locally advanced; 96 metastatic BCC)
from 36 countries were treated; 147 patients (12%) remained on study at time of reporting …
from 36 countries were treated; 147 patients (12%) remained on study at time of reporting …
[PDF][PDF] Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N Basset-Séguin, A Hauschild, R Kunstfeld… - European Journal of …, 2017 - academia.edu
Abstract Background: The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials. gov,
NCT01367665), assessed safety and efficacy of vismodegibda first-in-class Hedgehog …
NCT01367665), assessed safety and efficacy of vismodegibda first-in-class Hedgehog …
[HTML][HTML] Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N Basset-Séguin, A Hauschild, R Kunstfeld… - European Journal of …, 2017 - ejcancer.com
Abstract Background The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials. gov,
NCT01367665), assessed safety and efficacy of vismodegib—a first-in-class Hedgehog …
NCT01367665), assessed safety and efficacy of vismodegib—a first-in-class Hedgehog …
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
N Basset-Séguin, A Hauschild, R Kunstfeld… - European journal of …, 2017 - folia.unifr.ch
RESULTS Evaluable adult patients (N= 1215, 1119 locally advanced; 96 metastatic BCC)
from 36 countries were treated; 147 patients (12%) remained on study at time of reporting …
from 36 countries were treated; 147 patients (12%) remained on study at time of reporting …
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
A Hauschild, R Kunstfeld, J Grob, L Mortier… - EUROPEAN JOURNAL …, 2017 - air.unimi.it
Background The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials. gov,
NCT01367665), assessed safety and efficacy of vismodegibâ a first-in-class Hedgehog …
NCT01367665), assessed safety and efficacy of vismodegibâ a first-in-class Hedgehog …
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N Basset-Séguin, A Hauschild… - … journal of cancer …, 2017 - pubmed.ncbi.nlm.nih.gov
Background The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials. gov,
NCT01367665), assessed safety and efficacy of vismodegib-a first-in-class Hedgehog …
NCT01367665), assessed safety and efficacy of vismodegib-a first-in-class Hedgehog …